Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.

Slides:



Advertisements
Similar presentations
LTB4 production is elevated in preclinical and clinical lymphedema
Advertisements

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.
Fig. 3. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures.
Repeated administration of RGFP-966 improves short-term recognition and spatial memory in 3xTg-AD mice. Repeated administration of RGFP-966 improves short-term.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.
Transfer of miR-223 during neutrophil-epithelial cell interactions
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
Fig. 3. Features of PH in KRasLA2 transgenic mice.
In vivo function of MeTro sealants using rat incision model of lungs
Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.
Fig. 7. Role of PDE5 up-regulation in lung cancer–associated PH.
Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.
Fig. 1. Ketoprofen efficacy in a preclinical model of lymphedema can be attributed to its inhibition of LTB4. Ketoprofen efficacy in a preclinical model.
Fig. 1. The effect of dietary micronutrient deficiency on the configuration of a defined human gut microbiota established in gnotobiotic mice. The effect.
Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 4. Biomechanical properties of treated tibiae.
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 3. A circadian rhythm in fibroblast wound-healing response.
PVSRIPO-mediated APC activation occurs in immunosuppressive conditions
MRSA virulence proteins cause LMC death and diminished CLV function
Fig. 1 MT-2 ameliorates asthmatic pulmonary resistance.
Fig. 1 DMF promotes viral infection.
Fig. 4 Infection-induced CLV dysfunction is associated with decreased LMC coverage. Infection-induced CLV dysfunction is associated with decreased LMC.
Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.
Fig. 2. GPC3 expression in normal and tumor tissues.
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Fig. 8. Therapeutic effects of the transplantation of hiPSC-EPO–producing cells on renal anemia in adenine-treated mice. Therapeutic effects of the transplantation.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.
Fig. 5. In vivo characterization of adipogenesis by CT.
Fig. 3. Applying the rapid test to analyze human patient sera.
Fig. 6. A circadian rhythm in keratinocyte wound healing and a diurnal variation in human burn healing outcome. A circadian rhythm in keratinocyte wound.
Type 1 immunity drives metabolic disease but protects against NAFLD
Fig. 6 Malaria and l-arginine induce changes in the expression of inflammatory and angiogenic mediators in placental tissue by reverse transcription PCR.
Fig. 1. Muscles of LAMA2 MD patients and dyW/dyW mice contain high amounts of laminin-α4 and show deficits in BM. Muscles of LAMA2 MD patients and dyW/dyW.
Fig. 6. Apoptotic MSCs exert in vivo immunosuppression in a TH2-type inflammation model in the absence of cytotoxic cells. Apoptotic MSCs exert in vivo.
Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.
Fig. 4. Actin polymerization rhythms are required for circadian regulation of adhesion and wound-healing efficacy by fibroblasts. Actin polymerization.
Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.
Fig. 4. Perampanel ameliorates behavioral deficits in mice expressing the Thorase variants. Perampanel ameliorates behavioral deficits in mice expressing.
Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.
Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target
Fig. 2. Adenosine-induced SAN dysfunction recorded by optical mapping and SAN electrograms in ex vivo human hearts. Adenosine-induced SAN dysfunction recorded.
Fig. 5 Local gel scaffold for T cell memory response.
Fig. 4 Whisker deprivation–induced remapping is stable beyond the deprivation period. Whisker deprivation–induced remapping is stable beyond the deprivation.
Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.
Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.
Fig. 4. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model of ALS. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model.
Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice
Fig. 7. Treatment with DLK inhibitors reduces p-c-Jun and protects against neuronal and synaptic loss in vitro and in ALS mouse models. Treatment with.
Fig. 4. Features of PH in LLC1 lung tumor mice.
Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.
Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.
by Asuka Hirai-Yuki, Lucinda Hensley, David R
Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.
Fig. 4. Local application of FR provides prolonged protection against Gq-dependent airway constriction in normal and OVA-sensitized mice in vivo. Local.
Fig. 1. Specificity of FolamiR uptake in cancer cells in culture.
Fig. 7. Scale-up of AAV vector–mediated liver gene transfer of secretable GAA to nonhuman primates. Scale-up of AAV vector–mediated liver gene transfer.
Supplementary Figure 5: Effect of S48168 on normalized organ and skeletal muscle weights after 12 weeks of treatment for all the experimental groups from.
Adenosine-induced osteogenic differentiation of hiPSCs involves A2bR
Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.
Fig. 3. Features of PH in KRasLA2 transgenic mice.
Fig. 5. In vivo characterization of adipogenesis by CT.
Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.
Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models by Pauline Désogère, Luis F. Tapias, Lida P. Hariri,
In vivo prophylactic and therapeutic efficacy of C12G6 in mice
GCS-100 selectively kills KRAS-addicted lung tumors.
Presentation transcript:

Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease. Prophylactic treatment with GS-5734 reduces SARS-CoV disease. (A) Percent starting weight of Ces1c−/− mice infected with 104 PFU SARS-CoV MA15 treated beginning at −1 dpi with either vehicle (n = 42) or GS-5734 [25 mg/kg BID (n = 25) or 50 mg/kg QD (n = 28)]. (B) SARS-CoV lung titer of mice in (A) at 2 dpi (vehicle, n = 11; 50 mg/kg, n = 11; 25 mg/kg, n = 5) (left) or 5 dpi (vehicle, n = 13; 50 mg/kg, n = 13; 25 mg/kg, n = 4) (right). n.s., not significant. (C) Quantitation of SARS-CoV antigen in lung sections of mice in (A) at 2 dpi (left) (vehicle, n = 15; 50 mg/kg, n = 12; 25 mg/kg, n = 7) (left) or 5 dpi (vehicle, n = 10; 50 mg/kg, n = 12; 25 mg/kg, n = 4) (right). (D) Photomicrographs of SARS-CoV antigen staining (brown) and nuclei (blue) in lung sections from 2 and 5 dpi. (E) Photomicrographs of hematoxylin and eosin–stained mouse lung sections from 2 dpi highlighting the conducting airway lumen (aw). (F) WBP was used to measure the pulmonary function of mice in (A). Penh is a surrogate measure of bronchoconstriction. Expiration time (te) is the time taken to release one breath. End of expiratory pause (EEP) is the time between breaths. Symbols and error bars for (A), (B), (D), and (I) represent the mean and SD. The boxes encompass the 25th to 75th percentile, whereas the whiskers represent the range in (C), (E), and (F). Asterisk indicates statistical significance (P < 0.05) by two-way analysis of variance (ANOVA) with Tukey’s multiple comparison test for (D), (F), and (I) and with Kruskal-Wallis test for (E). Timothy P. Sheahan et al., Sci Transl Med 2017;9:eaal3653 Published by AAAS